Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

A Case of Organizing Pneumonia Associated with FOLFIRI Chemotherapy

  • Lee, Yoon Jeong (Department of Internal Medicine, Konkuk University Hospital, Konkuk University School of Medicine) ;
  • Kim, Jun-Hyun (Department of Internal Medicine, Konkuk University Hospital, Konkuk University School of Medicine) ;
  • Kim, Sun Woong (Department of Internal Medicine, Konkuk University Hospital, Konkuk University School of Medicine) ;
  • Kang, Won Chan (Department of Internal Medicine, Konkuk University Hospital, Konkuk University School of Medicine) ;
  • Kim, Soo Jung (Department of Internal Medicine, Konkuk University Hospital, Konkuk University School of Medicine) ;
  • Kim, Ji Hye (Department of Internal Medicine, Konkuk University Hospital, Konkuk University School of Medicine) ;
  • Kim, Sun Jong (Department of Internal Medicine, Konkuk University Hospital, Konkuk University School of Medicine)
  • Received : 2014.06.23
  • Accepted : 2014.08.29
  • Published : 2014.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

The combination chemotherapy of irinotecan with 5-fluorouracil and leucovorin (FOLFIRI regimen) was recently proven to be beneficial in patients with advanced colorectal cancer. Pulmonary toxicity is very rare in adverse effects of irinotecan. No case of organizing pneumonia (also known as bronchiolitis obliterans organizing pneumonia) associated with FOLFIRI chemotherapy has been reported. We experienced a case of a 62-year-old man who presented persistent dry cough and progressive dyspnea after receiving chemotherapy with FOLFIRI regimen. After surgical lung biopsy, the patient was diagnosed with FOLFIRI chemotherapy-induced organizing pneumonia which was successfully treated with steroid therapy.

Keywords

References

  1. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009;22:191-7. https://doi.org/10.1055/s-0029-1242458
  2. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7. https://doi.org/10.1016/S0140-6736(00)02034-1
  3. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
  4. Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Trigila N, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004;15:933-9. https://doi.org/10.1093/annonc/mdh217
  5. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992;10:16-20.
  6. Pasetto LM, Jirillo A, Iadicicco G, Rossi E, Paris MK, Monfardini S. FOLFOX versus FOLFIRI: a comparison of regimens in the treatment of colorectal cancer metastases. Anticancer Res 2005;25:563-76.
  7. Shimura T, Fuse N, Yoshino T, Minashi K, Tahara M, Doi T, et al. Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer. Ann Oncol 2010;21:2005-10. https://doi.org/10.1093/annonc/mdq061
  8. Pitot HC, Wender DB, O'Connell MJ, Schroeder G, Goldberg RM, Rubin J, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997;15:2910-9. https://doi.org/10.1200/JCO.1997.15.8.2910
  9. Yoshii N, Suzuki T, Nagashima M, Kon A, Kakihata K, Gemma A. Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports. Anticancer Drugs 2011;22: 563-8. https://doi.org/10.1097/CAD.0b013e3283473f28
  10. Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004;45:93-104. https://doi.org/10.1016/j.lungcan.2004.01.010
  11. Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-56. https://doi.org/10.1200/JCO.2005.04.9866
  12. Michielin O, Udry E, Periard D, Matzinger O, Lobrinus JA, Stupp R. Irinotecan-induced interstitial pneumonia. Lancet Oncol 2004;5:322-4. https://doi.org/10.1016/S1470-2045(04)01471-8
  13. Madarnas Y, Webster P, Shorter AM, Bjarnason GA. Irinotecan-associated pulmonary toxicity. Anticancer Drugs 2000; 11:709-13. https://doi.org/10.1097/00001813-200010000-00007

Cited by

  1. Fluorouracil/folinic acid/irinotecan : Organising pneumonia: case report vol.1541, pp.1, 2014, https://doi.org/10.1007/s40278-015-8281-5